BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24922069)

  • 1. Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus.
    Lood C; Tydén H; Gullstrand B; Sturfelt G; Jönsen A; Truedsson L; Bengtsson AA
    PLoS One; 2014; 9(6):e99386. PubMed ID: 24922069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?
    Lood C; Eriksson S; Gullstrand B; Jönsen A; Sturfelt G; Truedsson L; Bengtsson AA
    Lupus; 2012 Nov; 21(13):1423-32. PubMed ID: 22878256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.
    Peerschke EI; Yin W; Alpert DR; Roubey RA; Salmon JE; Ghebrehiwet B
    Lupus; 2009 May; 18(6):530-8. PubMed ID: 19395455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.
    Svenungsson E; Gustafsson JT; Grosso G; Rossides M; Gunnarsson I; Jensen-Urstad K; Larsson A; Ekdahl KN; Nilsson B; Bengtsson AA; Lood C
    Rheumatology (Oxford); 2020 Nov; 59(11):3264-3274. PubMed ID: 32259250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.
    Lonati PA; Scavone M; Gerosa M; Borghi MO; Pregnolato F; Curreli D; Podda G; Femia EA; Barcellini W; Cattaneo M; Tedesco F; Meroni PL
    Front Immunol; 2019; 10():773. PubMed ID: 31031764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
    Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
    Front Immunol; 2019; 10():885. PubMed ID: 31134052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.
    Cohen D; Koopmans M; Kremer Hovinga IC; Berger SP; Roos van Groningen M; Steup-Beekman GM; de Heer E; Bruijn JA; Bajema IM
    Arthritis Rheum; 2008 Aug; 58(8):2460-9. PubMed ID: 18668574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Roles of Antiphospholipid Antibodies in Generating Platelet-C4d in Systemic Lupus Erythematosus.
    Liu CC; Schofield T; Tang A; Manzi S; Ahearn JM
    Antibodies (Basel); 2017 Jul; 6(3):. PubMed ID: 31548524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus.
    Lood C; Tydén H; Gullstrand B; Nielsen CT; Heegaard NH; Linge P; Jönsen A; Hesselstrand R; Kahn R; Bengtsson AA
    Rheumatology (Oxford); 2017 Mar; 56(3):408-416. PubMed ID: 28031442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.
    Kao AH; McBurney CA; Sattar A; Lertratanakul A; Wilson NL; Rutman S; Paul B; Navratil JS; Scioscia A; Ahearn JM; Manzi S
    Transl Stroke Res; 2014 Aug; 5(4):510-8. PubMed ID: 24323718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet C4d is highly specific for systemic lupus erythematosus.
    Navratil JS; Manzi S; Kao AH; Krishnaswami S; Liu CC; Ruffing MJ; Shaw PS; Nilson AC; Dryden ER; Johnson JJ; Ahearn JM
    Arthritis Rheum; 2006 Feb; 54(2):670-4. PubMed ID: 16447243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation.
    Andrianova IA; Ponomareva AA; Mordakhanova ER; Le Minh G; Daminova AG; Nevzorova TA; Rauova L; Litvinov RI; Weisel JW
    J Autoimmun; 2020 Feb; 107():102355. PubMed ID: 31732191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martínez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Rueda M; Aguirre C
    Lupus; 2004; 13(12):927-33. PubMed ID: 15645748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
    Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
    Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus.
    Gartshteyn Y; Mor A; Shimbo D; Khalili L; Kapoor T; Geraldino-Pardilla L; Alexander RV; Conklin J; Dervieux T; Askanase AD
    Clin Immunol; 2021 Jul; 228():108755. PubMed ID: 33984497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.
    Kim KJ; Baek IW; Yoon CH; Kim WU; Cho CS
    Clin Exp Rheumatol; 2017; 35(5):823-830. PubMed ID: 28421990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.
    Kim MY; Guerra MM; Kaplowitz E; Laskin CA; Petri M; Branch DW; Lockshin MD; Sammaritano LR; Merrill JT; Porter TF; Sawitzke A; Lynch AM; Buyon JP; Salmon JE
    Ann Rheum Dis; 2018 Apr; 77(4):549-555. PubMed ID: 29371202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
    Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
    Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss.
    Cohen D; Buurma A; Goemaere NN; Girardi G; le Cessie S; Scherjon S; Bloemenkamp KW; de Heer E; Bruijn JA; Bajema IM
    J Pathol; 2011 Dec; 225(4):502-11. PubMed ID: 21688269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.